The information gap is where misinformation lives. We built PepSense to close it.

A few years ago, the people who would go on to build PepSense kept running into the same wall. Someone would ask a straightforward question about a peptide, what does the research actually show, what has been studied in humans versus animals, what is its regulatory status, and there was no good place to send them. The honest answer lived in a scattered constellation of Reddit threads, vendor marketing pages, podcast clips, and journal articles locked behind paywalls. Every source carried its own bias. Almost none of them cited anything.

That fragmentation is not a minor inconvenience. It is the core problem. When reliable information is hard to find, incentive-driven information rushes in to fill the vacuum. A supplement seller has every reason to overstate what a compound can do. A forum poster is repeating what worked for a friend of a friend. A podcast clip compresses a nuanced preclinical finding into a confident soundbite. None of these is a substitute for the underlying science, yet collectively they had become the default answer for millions of people trying to understand this field.

We are researchers, not marketers, and that distinction shaped everything. Our team includes a PhD biochemist with thirteen years of experience in peptide drug development, alongside data scientists and science writers who share a conviction that verified information should not be a privilege reserved for people with institutional journal access. We had spent our careers reading these studies. We knew the gap between what a paper actually reports and what the internet claims it reports was enormous, and widening.

So we built the tool we wished existed. PepSense is an AI answer engine trained on more than 300,000 published peptide studies from PubMed, ClinicalTrials.gov, and peer-reviewed journals, combined with detailed profiles of more than 200 compounds covering mechanism, safety data, and regulatory status. Every answer is source-cited, and every claim is anchored to where it came from. Just as importantly, the platform is built to be honest about uncertainty, clearly separating what has been observed in a test tube or an animal model from what has been established in human clinical trials or approved by the FDA.

That last point matters more than ever right now, because the regulatory picture is genuinely in motion. The FDA Pharmacy Compounding Advisory Committee is scheduled to meet on July 23 through 24, 2026, to vote on whether to recommend seven peptides toward the 503A Bulks List. That vote is non-binding and represents only an early step in a long rulemaking process, but the volume of confident, incorrect claims already circulating about what it means is exactly the kind of noise we were built to cut through. We track these developments in real time so that our answers reflect where things actually stand, not where a headline says they stand.

Our mission is simple to state and hard to execute: make peptide research accessible, verified, and current. Accessible, because the science should be readable by anyone willing to engage with it. Verified, because every answer should trace back to a real source. Current, because a field moving this fast demands information that keeps pace. The demand is undeniable, and the gap between that demand and trustworthy answers has never been wider. That gap is precisely where misinformation thrives, and closing it is the entire reason we exist.